Encapsulated antimicrobial precursors for non-antibiotic treatment of MDRO in poultry.
Lead Participant:
GAMA HEALTHCARE LIMITED
Abstract
The use of antimicrobial treatments in agriculture is vital in protecting animal health and aiding the production
of safe and nutritious food. However, previous overuse, and continued use of antibiotics in agriculture has been
attributed to the rise in multi-drug resistance (MDR) bacteria, which can lead to ill-health and even death in
humans if infected. MDR bacteria have been identified in large numbers of animals and raw food products,
representing a major risk to public health and food system security. This is especially important in China and
developing countries which rely heavily on animal products for nutrition and livelihoods, with chicken being the
fastest growing protein source. GAMA Healthcare have developed an alternative antimicrobial treatment to
conventional antibiotics by coupling a cancer medicine delivery system (microparticles) with a new class of
short-lived antiseptic, which will be applied to reduce MDR bacteria in on chicken farms. The technology can be
customised to meet the specific needs of the end-user, delivering a toxic payload to bacteria present within the
animal and can be produced cheaply and safely, making it suitable for the agricultural/veterinary market.
of safe and nutritious food. However, previous overuse, and continued use of antibiotics in agriculture has been
attributed to the rise in multi-drug resistance (MDR) bacteria, which can lead to ill-health and even death in
humans if infected. MDR bacteria have been identified in large numbers of animals and raw food products,
representing a major risk to public health and food system security. This is especially important in China and
developing countries which rely heavily on animal products for nutrition and livelihoods, with chicken being the
fastest growing protein source. GAMA Healthcare have developed an alternative antimicrobial treatment to
conventional antibiotics by coupling a cancer medicine delivery system (microparticles) with a new class of
short-lived antiseptic, which will be applied to reduce MDR bacteria in on chicken farms. The technology can be
customised to meet the specific needs of the end-user, delivering a toxic payload to bacteria present within the
animal and can be produced cheaply and safely, making it suitable for the agricultural/veterinary market.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
GAMA HEALTHCARE LIMITED | £99,217 | £ 59,530 |
  | ||
Participant |
||
SRUC | £320,957 | £ 320,957 |
CIELIVESTOCK LIMITED | £103,602 | £ 103,602 |
AGA NANOTECH LTD | £7,500 | £ 5,250 |
AGA2 TECH LIMITED |
People |
ORCID iD |
Dharmit Mistry (Project Manager) |